ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
Conclusions The RP2D for AZD5363 is 320 mg BID, 4 days on/3 days off, in combination with full dose DP for mCRPC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Diarrhoea | Docetaxel | Drugs & Pharmacology | Investigational New Drugs | Oral Cancer | Prednisolone | Prostate Cancer | Radiography | Taxotere | Toxicology